REGN stock verdict - Growth
REGN
Regeneron Pharmaceuticals, Inc.
GROWTHHealthcare
$656.01
Watch (wait for dip)
$656.01
Heavy$393.14Buy$524.19Fair$655.23Exit$786.28
FUNDAMENTAL60
TECHNICAL47
TRUST SCORE
100High
confidence in this read — data completeness, earnings quality & coverage
Neutral · EMA20 655.73 · EMA50 658.7 · EMA200 686.54 · RSI 51.1 · MACD below signal
PROS
- Reasonable forward P/E of 12.0× on analyst estimates
- Conservative balance sheet — debt-to-equity of 0.09
- Converts 25% of revenue into free cash flow
- High gross margin of 86% (3-yr avg)
CONS
No red flags detected.
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 111% of net income — profit is backed by real cash
✓Low accruals — reported profit tracks the cash actually generated
✓Receivables growing in line with sales
SECTOR PEERS
Analysis as of 2026-07-27 · price live, fundamentals from latest filings
FAQ
Why is REGN rated Growth?
REGN (Regeneron Pharmaceuticals, Inc.) is rated Growth because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Watch (wait for dip). Reasonable forward P/E of 12.0× on analyst estimates and Conservative balance sheet — debt-to-equity of 0.09
Is REGN overvalued right now?
REGN is trading at $656.01 versus an estimated fair value of $655.23. That puts the stock in growth territory on this framework. The page shows the specific downside checks behind that call.
What should I watch before acting on REGN?
Watch the trust score of 100, the earnings-quality checks, and any red flags. The page includes the key cautions and a plain-English summary.